Merck & Co. is putting down $30 million cash to buy Yale spinout Modifi Biosciences, a deal that includes a preclinical asset ...

Eye drug maker Ocuphire Pharma is acquiring gene therapy developer Opus Genetics in an all-stock transaction that will see ...

Alto Neuroscience hit a bum note in an early test of its precision neuropsychiatry model. | Alto Neuroscience hit a bum note ...

GSK is pumping £50 million (about $65 million) into a five-year collaboration with the University of Cambridge and Cambridge ...

Last week, the outgoing leader of the FDA’s devices center, long-time chief Jeff Shuren, M.D., endorsed acting head Michelle ...

The biotech engaged with the FDA on alternative pathways to approval after seeing safety and efficacy data from the phase 1/2 ...

The FDA has granted a de novo clearance to a new type of stent designed to hold open the passages down the windpipe and into ...

Otsuka Pharmaceutical’s kidney disease drug has hit the primary endpoint of a phase 3 trial by demonstrating in an interim ...

China-based Minghui Pharmaceutical has linked its thyroid eye disease treatment to a reduction in eye bulging in a small ...

R&D software developer Dotmatics is rolling out a platform for discovering and developing therapeutic antibodies and proteins ...

Editas Medicine is pushing its in vivo gene therapy strategy to the top of its agenda, boasting proof-of-concept data and ...

Roche has returned the rights to UCB’s anti-tau antibody bepranemab, walking away from a $120 million bet on the Alzheimer’s ...